Skip to main content

Table 6 Items regarding CS5: Patient with non-functioning GEP-NET, non-susceptible to surgery or to loco-regional treatment, with Ki-67 > 10 %, ECOG ≤2, AND POSITIVE OCTREOSCAN®: Is SSA treatment initiated? [36, 59]

From: Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program

  Previous rounda Median (p25-p75) Median range Participants in median range n (%) Result
41. The use of SSA in monotherapy in these patients is reasonable in patients with Ki-67 <20 %. 50.8 %: 7–9 7 (7–8) 7–9 48 (84.2) C - A
42. The use of SSA in monotherapy in these patients is reasonable in case of low tumor load (hepatic ≤25 % and no extra-hepatic disease). 63.1 %: 7–9 8 (7–8) 7–9 50 (87.7) C - A
43. The use of SSA in monotherapy in these patients is reasonable in case of NETs of gastrointestinal origin. 52.3 %: 7–9 7 (7–8) 7–9 49 (86) C - A
44. In case of important comorbidities, SSAs are an option in these patients.   8 (7–9) 7–9 56 (86.2) C - A
45. In these patients with Ki-67 from 10 to 20 % and/or high tumor load (extra-hepatic and/or hepatic >25 %) and/or NET of pancreatic origin, treatment is usually initiated with chemotherapy. 66.2 %: 7–9 7 (7–8) 7–9 48 (84.2) C - A
46. In these patients with Ki-67 from 10 to 20 % and/or high tumor load (extra-hepatic and/or hepatic >25 %) and/or NET of pancreatic origin, treatment is usually initiated with molecular targeted drugs (with the possibility of combination with SSA).   7 (6–8) 7–9 45 (69.2) C - A
47. If discrepancy exists between the degree of cellular proliferation and the octreoscan® results, it is recommended to perform 18FDG-PET-TAC to help making a therapeutic decision. 53.8 %: 7–9 7 (7–8) 7–9 46 (80.7) C - A
48. If discrepancy exists between the degree of cellular proliferation and the octreoscan® results, a re-biopsy of the growing lesions will be considered. 64.4 %: 7–9 7 (7–8) 7–9 53 (93) C - A
  1. CS Clinical situation, SSAs Somatostatin analogs, GEP Gastroenteropancreatic, NET Neuroendocrine tumor, C consensus, NC non-consensus, A Agreement
  2. aOnly applies to statements with 2 rounds; participant % in median range: median range